Biogen Reports Strong Q1 with Revenue Growth Driven by Rare Disease Therapies
Biogen Inc. reported strong Q1 2025 performance with $2.43 billion in revenue, driven by demand for its rare disease therapies, despite lowering its full-year earnings guidance.
2 minutes to read